losartan has been researched along with Cardiomyopathy, Dilated in 19 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cardiomyopathy, Dilated: A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty patients with moderately severe chronic heart failure received enalapril 10 mg and losartan 50 mg on 2 separate occasions in a single-blind, randomized, crossover design." | 5.09 | Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. ( Flapan, AD; Goodfield, NE; Ludlam, CA; Newby, DE, 1999) |
| "The influence of chronic administration of losartan on gap junction conductance (gj), conduction velocity and interstitial fibrosis was investigated in the failing heart of 4-month-old cardiomyopathic hamsters (TO-2)." | 3.73 | Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart. ( De Mello, WC; Specht, P, 2006) |
| "The dystrophinopathies include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM)." | 2.58 | Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. ( Bourke, JP; Bueser, T; Quinlivan, R, 2018) |
| "We treated a dilated cardiomyopathy-linked mouse model expressing a mutant tropomyosin (Tm-E54K) for 3 months with either TRV120067, a β-arrestin 2-biased ligand of the angiotensin II receptor, or losartan, an angiotensin II receptor blocker." | 1.46 | Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy. ( Cowan, CL; Li, J; Russell, B; Ryba, DM; Solaro, RJ; Wolska, BM, 2017) |
| "Here, we determined that dilated cardiomyopathy (DCM) in fibrillin 1-deficient mice is a primary manifestation resulting from ECM-induced abnormal mechanosignaling by cardiomyocytes." | 1.40 | Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. ( Bénard, L; Carta, L; Chemaly, ER; Chiu, E; Cook, JR; Costa, KD; Hajjar, RJ; Hampton, TG; Ramirez, F; Rao, SK; Yurchenco, P, 2014) |
| "Nifedipine-treated animals displayed hemodynamics, LV dilatation, hypertrophy, and loss of function similar to those of the untreated group." | 1.35 | Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. ( Arsenault, M; Beaudoin, J; Champetier, S; Couet, J; Lachance, D; Plante, E; Roussel, E, 2009) |
| "Coxiella burnetii myocarditis is a rare but severe clinical form of acute Q fever." | 1.31 | [Acute myocardial failure in a young man: Q-fever myocarditis]. ( Climent, V; López, I; Manso, MI; Murcia, J; Reus, S; Tello, A, 2002) |
| "Losartan treatment was associated with a modest reduction of cardiac 4-hydroxyproline concentration, and a significant reduction of both MMP-1 and MMP-2 activities." | 1.31 | Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. ( Dixon, IM; Hao, J; Reid, NL; Roth, JC, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, M | 1 |
| Pan, F | 1 |
| Liu, Y | 1 |
| Li, Z | 1 |
| Zhou, X | 1 |
| Meng, X | 1 |
| Liu, L | 1 |
| Ge, S | 1 |
| Bourke, JP | 1 |
| Bueser, T | 1 |
| Quinlivan, R | 1 |
| Cook, JR | 1 |
| Carta, L | 1 |
| Bénard, L | 1 |
| Chemaly, ER | 1 |
| Chiu, E | 1 |
| Rao, SK | 1 |
| Hampton, TG | 1 |
| Yurchenco, P | 1 |
| Costa, KD | 1 |
| Hajjar, RJ | 1 |
| Ramirez, F | 1 |
| Ryba, DM | 1 |
| Li, J | 1 |
| Cowan, CL | 1 |
| Russell, B | 1 |
| Wolska, BM | 1 |
| Solaro, RJ | 1 |
| Crespo, MJ | 1 |
| Cruz, N | 1 |
| Altieri, PI | 1 |
| Escobales, N | 1 |
| Chua, S | 1 |
| Sheu, JJ | 1 |
| Chang, LT | 1 |
| Lee, FY | 1 |
| Wu, CJ | 1 |
| Sun, CK | 1 |
| Yip, HK | 1 |
| Plante, E | 1 |
| Lachance, D | 1 |
| Beaudoin, J | 1 |
| Champetier, S | 1 |
| Roussel, E | 1 |
| Arsenault, M | 1 |
| Couet, J | 1 |
| Murcia, J | 1 |
| Reus, S | 1 |
| Climent, V | 1 |
| Manso, MI | 1 |
| López, I | 1 |
| Tello, A | 1 |
| De Mello, WC | 1 |
| Specht, P | 1 |
| Kanda, T | 1 |
| Araki, M | 1 |
| Nakano, M | 1 |
| Imai, S | 1 |
| Suzuki, T | 1 |
| Murata, K | 1 |
| Kobayashi, I | 1 |
| Guazzi, M | 1 |
| Melzi, G | 1 |
| Agostoni, P | 1 |
| Goodfield, NE | 1 |
| Newby, DE | 1 |
| Ludlam, CA | 1 |
| Flapan, AD | 1 |
| Bastien, NR | 1 |
| Juneau, AV | 1 |
| Ouellette, J | 1 |
| Lambert, C | 1 |
| Dixon, IM | 1 |
| Hao, J | 1 |
| Reid, NL | 1 |
| Roth, JC | 1 |
| Petretta, M | 2 |
| Spinelli, L | 2 |
| Marciano, F | 1 |
| Apicella, C | 1 |
| Vicario, ML | 2 |
| Testa, G | 1 |
| Volpe, M | 1 |
| Bonaduce, D | 2 |
| Wittstein, IS | 1 |
| Kass, DA | 1 |
| Pak, PH | 1 |
| Maughan, WL | 1 |
| Fetics, B | 1 |
| Hare, JM | 1 |
| Masutomo, K | 1 |
| Makino, N | 1 |
| Fushiki, MS | 1 |
| Schiavone, D | 1 |
| De Santis, V | 1 |
| Condorelli, M | 1 |
| Nikolaidis, LA | 1 |
| Doverspike, A | 1 |
| Huerbin, R | 1 |
| Hentosz, T | 1 |
| Shannon, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions[NCT01322165] | 3,706 participants (Actual) | Observational | 2007-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2018 |
2 trials available for losartan and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiomyopathy, Dilated; | 1997 |
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 1999 |
16 other studies available for losartan and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Echocardiographic Strain Analysis for the Early Detection of Myocardial Structural Abnormality and Initiation of Drug Therapy in a Mouse Model of Dilated Cardiomyopathy.
Topics: Animals; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Disease Models, Animal; Echocardiography; | 2017 |
Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomyopathy, Dilated; Child; Cross-Secti | 2014 |
Long-Term Biased β-Arrestin Signaling Improves Cardiac Structure and Function in Dilated Cardiomyopathy.
Topics: Angiotensin Receptor Antagonists; Animals; beta-Arrestins; Calcium; Cardiomyopathy, Dilated; Disease | 2017 |
Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Comparison of losartan and carvedilol on attenuating inflammatory and oxidative response and preserving energy transcription factors and left ventricular function in dilated cardiomyopathy rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Carbazoles; Cardiomyo | 2008 |
Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic V | 2009 |
[Acute myocardial failure in a young man: Q-fever myocarditis].
Topics: Acute Disease; Adult; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antibodies, Bacterial; Cardiomy | 2002 |
Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomyopathy, Dilated; Cell Communication; Crice | 2006 |
Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Captopril; Cardiomyopathy, Dilated; D | 1995 |
Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival.
Topics: Alanine Transaminase; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Angiot | 1999 |
Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blotting, | 2000 |
Effects of losartan treatment on cardiac autonomic control during volume loading in patients with DCM.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Autonomic Nervous System; Blood Pressure; Cardiomyopa | 2000 |
Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiomyopath | 2001 |
Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters.
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Western; Body Weight; Cardiomyopathy, Dilated; | 2001 |
Losartan treatment and left ventricular filling during volume loading in patients with dilated cardiomyopathy.
Topics: Adult; Aldosterone; Analysis of Variance; Anti-Arrhythmia Agents; Antihypertensive Agents; Blood Flo | 2002 |
Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Car | 2002 |